D Orazio & Associates Inc. Lowers Position in Pfizer Inc. (NYSE:PFE)

D Orazio & Associates Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.2% during the third quarter, HoldingsChannel.com reports. The firm owned 7,158 shares of the biopharmaceutical company’s stock after selling 389 shares during the period. D Orazio & Associates Inc.’s holdings in Pfizer were worth $207,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in PFE. China Universal Asset Management Co. Ltd. acquired a new stake in Pfizer during the first quarter worth about $315,000. Koshinski Asset Management Inc. grew its holdings in shares of Pfizer by 20.5% during the 1st quarter. Koshinski Asset Management Inc. now owns 24,265 shares of the biopharmaceutical company’s stock worth $673,000 after purchasing an additional 4,130 shares during the period. Beacon Investment Advisory Services Inc. increased its position in Pfizer by 27.8% during the 1st quarter. Beacon Investment Advisory Services Inc. now owns 70,567 shares of the biopharmaceutical company’s stock worth $1,958,000 after purchasing an additional 15,347 shares in the last quarter. Brighton Jones LLC raised its holdings in Pfizer by 99.4% in the first quarter. Brighton Jones LLC now owns 122,276 shares of the biopharmaceutical company’s stock valued at $3,393,000 after buying an additional 60,956 shares during the period. Finally, Dorsey & Whitney Trust CO LLC lifted its position in Pfizer by 16.0% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 72,467 shares of the biopharmaceutical company’s stock valued at $2,011,000 after buying an additional 9,989 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on PFE. StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. UBS Group boosted their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company increased their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Citigroup initiated coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Finally, Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Up 2.0 %

NYSE PFE opened at $26.72 on Thursday. The company has a market capitalization of $151.42 billion, a price-to-earnings ratio of 36.11, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The company’s fifty day moving average price is $28.80 and its two-hundred day moving average price is $28.68.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.17) earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.29%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.